Senzime 将来の成長

Future 基準チェック /26

Senzime利益と収益がそれぞれ年間75.2%と71.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-4.9% 77.4%なると予測されています。

主要情報

75.2%

収益成長率

77.4%

EPS成長率

Medical Equipment 収益成長	36.9%
収益成長率	71.9%
将来の株主資本利益率	-4.9%
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

Feb 16

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

Jan 19

Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?

Dec 23

What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?

Nov 26

業績と収益の成長予測

OM:SEZI - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	277	1	2	30	3
12/31/2025	149	-62	-51	-33	3
12/31/2024	66	-120	-125	-108	2
9/30/2024	55	-131	-129	-113	N/A
6/30/2024	47	-130	-125	-113	N/A
3/31/2024	41	-131	-119	-110	N/A
12/31/2023	36	-134	-122	-114	N/A
9/30/2023	29	-138	-121	-114	N/A
6/30/2023	24	-137	-164	-158	N/A
3/31/2023	19	-143	-159	-153	N/A
12/31/2022	14	-133	-142	-137	N/A
9/30/2022	13	-114	-133	-128	N/A
6/30/2022	11	-104	-86	-80	N/A
3/31/2022	12	-86	-84	-80	N/A
12/31/2021	11	-82	-84	-81	N/A
9/30/2021	11	-74	-78	-76	N/A
6/30/2021	11	-66	-65	-64	N/A
3/31/2021	8	-56	-50	-50	N/A
12/31/2020	9	-47	-39	-38	N/A
9/30/2020	9	-41	-31	-30	N/A
6/30/2020	9	-36	-25	-23	N/A
3/31/2020	9	-32	-25	-22	N/A
12/31/2019	7	-33	-30	-27	N/A
9/30/2019	7	-34	-29	-25	N/A
6/30/2019	4	-33	-35	-28	N/A
3/31/2019	4	-30	-33	-25	N/A
12/31/2018	3	-24	-27	-17	N/A
9/30/2018	1	-19	-27	-16	N/A
6/30/2018	0	-16	N/A	-13	N/A
3/31/2018	0	-13	N/A	-11	N/A
12/31/2017	0	-13	N/A	-12	N/A
9/30/2017	0	-13	N/A	-13	N/A
6/30/2017	1	-12	N/A	-14	N/A
3/31/2017	2	-12	N/A	-13	N/A
12/31/2016	2	-9	N/A	-10	N/A
9/30/2016	1	-8	N/A	-8	N/A
6/30/2016	1	-8	N/A	-7	N/A
3/31/2016	0	-8	N/A	-6	N/A
12/31/2015	0	-8	N/A	-6	N/A
9/30/2015	0	-7	N/A	-6	N/A
6/30/2015	0	-7	N/A	-5	N/A
3/31/2015	0	-7	N/A	-5	N/A
12/31/2014	1	-6	N/A	-4	N/A
9/30/2014	1	-6	N/A	-4	N/A
6/30/2014	1	-5	N/A	-4	N/A
3/31/2014	1	-5	N/A	-5	N/A
12/31/2013	1	-6	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SEZI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SEZI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SEZI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SEZIの収益 ( 71.9% ) Swedish市場 ( 0% ) よりも速いペースで成長すると予測されています。

高い収益成長: SEZIの収益 ( 71.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SEZI 3 年以内に赤字になると予測されています。

Senzime 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Senzime AB (publ) Provides Earnings Guidance for 2025

Consensus revenue estimates fall by 34%

Forecast breakeven date pushed back to 2024

Price target decreased to kr34.00

Price target decreased to kr34.00

Recent updates

New minor risk - Profitability

Chairman of the Board recently bought kr163k worth of stock

Chairman of the Board recently bought kr163k worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025

Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024

Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference

Second quarter 2024 earnings: Revenues miss analyst expectations

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

New minor risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Chief Financial Officer recently bought kr67k worth of stock

Chief Financial Officer recently bought kr67k worth of stock

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

New major risk - Financial position

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Independent Chairman recently bought kr740k worth of stock

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Less than half of directors are independent

Senzime AB (publ) Provides Earnings Guidance for 2025

Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021)

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Consensus revenue estimates fall by 34%

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to kr34.00

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Will Senzime (STO:SEZI) Spend Its Cash Wisely?

Price target decreased to kr34.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

New 90-day low: kr21.50

Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return

We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely

New 90-day high: kr25.80

Senzime AB (publ) Gets US Patent for OnZurf Probe